CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 30(Granted Patents)

Location History:

Nr Saffron Walden, GB (2010 - 2011)
Walden, GB (2011)
Sharnbrook, GB (2009 - 2014)
Cambridge, GB (2015 - 2018)

Company Filing History:

4 out of 7

Neurovive Pharmaceutical Ab

patents

4 out of 18

Biotica Technology Limited

Isomerase Therapeutics, Ltd.

patents

5. 1 out of 1

The University of Oviedo

patent

6. 1 out of 48

Buck Institute for Research on Aging

patents

where one patent can have more than one assignee

Years Active: 2009-2018

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9976165 - Methods for increasing molecular diversity of polyketides and non-ribosomal proteins (2018-05-22),

2. 9505773 - Rapamycin analogues and their pharmaceutical use (2016-11-29),

3. 9382266 - Rapamycin analogue (2016-07-05),

4. 9271977 - Sanglifehrin derivatives and methods for their production (2016-03-01),

5. 9139613 - Macrocyclic compounds and methods for their production (2015-09-22),

6. 9119853 - Sanglifehrin based compounds (2015-09-01),

7. 9090657 - Compound and methods for its production (2015-07-28),

8. 8624009 - Spinosyn-producing polyketide synthases (2014-01-07),

9. 8008318 - 39-desmethoxy derivatives of rapamycin (2011-08-30),

10. 7897608 - 39-desmethoxy-39-methyl derivatives of rapamycin (2011-03-01),

11. 7648996 - 39-desmethoxy derivatives of rapamycin (2010-01-19),

12. 7626010 - Spinosyn-producing polyketide synthases (2009-12-01),

13. 7560252 - Borrelidin-producing polyketide synthase and its use (2009-07-14),

Title: Barrie Wilkinson: A Pioneer in Molecular Diversity Innovations

Introduction

Barrie Wilkinson is a prominent inventor based in Cambridge, GB, with an impressive portfolio of 13 patents. His innovative contributions primarily lie in the fields of molecular biology and pharmaceuticals, particularly focusing on polyketides and non-ribosomal peptides.

Latest Patents

Among his latest patents, Barrie has developed methods for increasing the molecular diversity of polyketides and non-ribosomal proteins. This particular method utilizes recombination to efficiently adjust the number of modules in the polyketide synthase or non-ribosomal peptide synthetase, which enhances the molecular variety of these compounds. Another noteworthy patent involves the creation of novel rapamycin analogues and their pharmaceutical applications. These analogues exhibit FKBP and/or MIP inhibitory activity while having reduced mTOR inhibitory effects, showing promise as potential bacterial virulence inhibitors.

Career Highlights

Throughout his career, Barrie has worked with notable companies such as Biotica Technology Limited and Neurovive Pharmaceutical Ab. His work with these organizations has significantly impacted the development of new therapeutic agents derived from his inventive methodologies.

Collaborations

Barrie has collaborated with talented individuals in the industry, including Steven James Moss and Matthew Alan Gregory. These partnerships have enhanced his research and innovation efforts, leading to noteworthy advancements in his field.

Conclusion

With a strong focus on molecular diversity and pharmaceutical applications, Barrie Wilkinson has solidified his reputation as an influential inventor in Cambridge. His patents reflect his commitment to advancing science and improving therapeutic options, making a lasting impact in the world of biotechnology.

This text is generated by artificial intelligence and may not be accurate.